摘要
目的 探讨乌司他丁联合右美托咪定对重型颅脑损伤术后患者认知功能及血清S100钙结合蛋白B(S100B)、神经元特异性烯醇化酶(NSE)的影响。方法 选取2021年1月至2022年9月江西省中西医结合医院收治的80例重型颅脑损伤手术患者作为研究对象,按照随机数字表法将其分为对照组和试验组,每组40例。对照组采取常规治疗,试验组在对照组基础上采取乌司他丁联合右美托咪定治疗。比较两组术前和术后1、3、7 d的血清S100B、NSE水平,以及术后入ICU时和术后3、7 d的认知功能[简易精神状态检查(MMSE)、蒙特利尔认知量表(MoCA)]评分及用药期间不良反应的发生情况。结果 术后1、3、7 d,两组血清S100B、NSE水平低于术前,且试验组低于对照组,差异均有统计学意义(P<0.05)。术后3、7 d,两组MMSE评分、MoCA评分高于术后入ICU时,且试验组高于对照组,差异均有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 乌司他丁联合右美托咪定可改善重型颅脑损伤术后患者的血清S100B、NSE水平,提高患者的认知功能,且不会增加患者的不良反应。
Objective To investigate the effects of ulinastatin combined with dexmedetomidine on cognitive function,serum S100 calcium binding protein B(S100B),and neuron specific enolase(NSE)in patients with severe craniocerebral injury after surgery.Methods From January 2021 to September 2022,80 patients with severe craniocerebral injury after surgery admitted to Jiangxi Province Integrated Traditional Chinese and Western Medicine Hospital were randomly divided into control group and experimental group,40 cases in each group.The control group received routine treatment,while the experimental group received ulinastatin combined with dexmedetomidine treatment on the basis of the control group.The levels of S100B and NSE before operation and on the 1st day,3rd day and 7th day postoperatively,as well as the cognitive function[mini mental state examination(MMSE),montreal cognitive assessment(MoCA)]scores at admission to the ICU and on the 3rd day and 7th days postoperatively,and the adverse reactions during medication were compared between the two groups.Results On the 1st day,3rd day,and 7th day after surgery,the serum S100B and NSE levels in the two groups were lower than those before surgery,and the serum S100B and NSE levels in the experimental group were lower than those in the control group,with statistically significant difference(P<0.05).On the 3rd day and 7th day after surgery,the MMSE scores and MoCA scores in the two groups were higher than those at admission to ICU after surgery,and the MMSE scores and MoCA scores in the experimental group were higher than those in the control group,with statistically significant differenc(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Ulinastatin combined with dexmedetomidine can improve the levels of serum S100B and NSE in patients with severe craniocerebral injury after surgery,and improve their cognitive function,without increasing adverse reactions.
作者
马悦茗
欧阳丽芬
龚志翔
何青云
李建斌
王龙海
董双虎
康骏
MA Yueming;OUYANG Lifen;GONG Zhixiang;HE Qingyun;LI Jianbin;WANG Longhai;DONG Shuanghu;KANG Jun(Department of Critical Care Medical,Jiangxi Province Integrated Traditional Chinese and Western Medicine Hospital,Nanchang,Jiangxi 330000,China;Department of Neurosurgery,Jiangxi Province Integrated Traditional Chinese and Western Medicine Hospital,Nanchang,Jiangxi 330000,China)
出处
《检验医学与临床》
CAS
2023年第15期2174-2177,共4页
Laboratory Medicine and Clinic
基金
江西省卫生健康委员会科技计划项目(202311244)。
